Protective effects of centrally acting sympathomodulatory drugs on myocardial ischemia induced by sympathetic overactivity in rabbits

M. Catelli¹, J. Feldman², P. Bousquet³ and E. Tibiriçá³

¹Departamento de Fisiologia e Farmacodinâmica, Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro, RJ, Brasil
²Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Université Louis Pasteur, Strasbourg, France

Abstract

It is recognized that an imbalance of the autonomic nervous system is involved in the genesis of ventricular arrhythmia and sudden death during myocardial ischemia. In the present study we investigated the effects of clonidine and rilmenidine, two centrally acting sympathomodulatory drugs, on an experimental model of centrally induced sympathetic hyperactivity in pentobarbital-anesthetized New Zealand albino rabbits of either sex (2-3 kg, N = 89). We also compared the effects of clonidine and rilmenidine with those of propranolol, a β-blocker, known to induce protective cardiovascular effects in patients with ischemic heart disease. Central sympathetic stimulation was achieved by intracerebroventricular injection of the excitatory amino acid L-glutamate (10 μmol), associated with inhibition of nitric oxide synthesis with L-NAME (40 mg/kg, iv). Glutamate triggered ventricular arrhythmia and persistent ST-segment shifts in the ECG, indicating myocardial ischemia. The intracisternal administration of clonidine (1 μg/kg) and rilmenidine (30 μg/kg) or of a nonhypotensive dose of rilmenidine (3 μg/kg) decreased the incidence of myocardial ischemia (25, 14 and 25%, respectively, versus 60% in controls) and reduced the mortality rate from 40% to 0.0, 0.0 and 12%, respectively. The total number of ventricular premature beats per minute fell from 30 ± 9 in the control group to 7 ± 3, 6 ± 3 and 2 ± 2, respectively. Intravenous administration of clonidine (10 μg/kg), rilmenidine (300 μg/kg) or propranolol (500 μg/kg) elicited similar protective effects. We conclude that clonidine and rilmenidine present cardioprotective effects of central origin, which can be reproduced by propranolol, a lipophilic β-blocking agent.

Key words
- Autonomic nervous system
- Antihypertensive agents
- Antiarrhythmic agents
- Ischemia
- Sudden death

Introduction

Activation of the central sympathetic nervous system has proved to be a definitive pathophysiological feature in cardiovascular diseases such as primary arterial hypertension, heart failure and arrhythmogenesis during myocardial ischemia (1). In fact, experimental and clinical evidence suggests that sudden cardiac death in ischemic patients is mediated, at least in part, by the central nervous system (2-4). Moreover, an imbal-
ance of the autonomic nervous system, characterized by increased sympathetic activity and reduced vagal activity, results in myocardial electrical instability and promotes the occurrence of ischemic events (5,6). Consequently, the pharmacological modulation of the sympathetic activity with ß-blockers (7) as well as the increase of vagal tonus using muscarinic agonists (3) or cholinesterase inhibitors such as pyridostigmine (8) elicit cardioprotective effects. Sympathetic hyperactivity can also be modulated by drugs acting directly on its site of origin, i.e., the central nervous system. In this context, first generation centrally acting antihypertensive drugs such as clonidine have been used in the treatment of essential arterial hypertension (9). Nevertheless, the antihypertensive effect of this class of drugs was frequently accompanied by important central side effects such as sedation and dry mouth, resulting in a loss of interest in its clinical use (9). In the past two decades, after the existence of a new class of pharmacological receptors was demonstrated, the nonadrenergic specific imidazoline receptors (10), a second generation of clonidine-like drugs was developed. It was also possible to demonstrate a dissociation between the pharmacological mechanisms involved in the hypotensive effect of imidazoline agents (imidazoline receptors in the ventrolateral medulla) (11-13) and the one responsible for their sedative action (α2-adrenoceptors in the locus coeruleus) (12,14). In fact, clonidine-derived imidazoline drugs such as rilmenidine and moxonidine have proved to be effective for the treatment of mild to moderate arterial hypertension without presenting significant sedative effects (9).

The purpose of the present study was to determine the effects of systemic and central administration of clonidine and rilmenidine on ventricular arrhythmia, myocardial ischemia and mortality induced by central sympathetic stimulation with L-glutamate in Nω-nitro-L-arginine methyl ester (L-NAME)-treated and pentobarbital-anesthetized rabbits. We also compared, in the same experimental model, the protective effects of clonidine and rilmenidine with those obtained by systemic administration of propranolol, a ß-blocker known to present beneficial cardiovascular effects in patients with myocardial ischemia (7,15).

Material and Methods

Animals and hemodynamic measurements

The investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). New Zealand albino rabbits of either sex (2-3 kg, N = 89) were anesthetized with sodium pentobarbital (40 mg/kg) administered through the marginal vein of the ear; anesthesia was complemented with second intravenous (iv) injection of 5 mg/kg pentobarbital before the control period (see below). After induction of anesthesia, a tracheotomy was performed and neuromuscular blockade was induced with pancuronium bromide (1 mg/kg, iv). The rabbits were ventilated artificially with room air using a small animal ventilator (Model 7025, Biological Research Apparatus, Ugo Basile, Varese, Italy) at a rate of 25 cycles/min and a tidal volume of 10 ml/kg. Rectal temperature was maintained at 37°C with a homeothermic blanket system (Harvard Apparatus, Boston, MA, USA). The right femoral vein was catheterized to permit iv injection. The instantaneous arterial pressure was monitored continuously with a Gould P23D transducer through a catheter placed in the abdominal aorta via the right femoral artery. Left ventricular pressures (LVP) were measured with a high fidelity micromanometer-tipped size 4F catheter (Millar Mikro-tip catheter model SPR-249, Millar Instruments Inc., Houston, TX, USA) placed in the left ventricle via the right carotid artery. Ana-
logue pressure signals were digitized at a sampling frequency of 1 Hz and stored in a computer for later processing using data acquisition software for hemodynamic experiments (Heamodyn for Windows, Hugo Sacks Elektronik, March-Hugstetten, Germany). Heart rate (HR), systolic, diastolic and mean arterial pressures (MAP), LVP and the maximal rates of LVP development (+dP/dt max) and fall (-dP/dt max) were measured. Electrocardiograph (ECG) leads were attached to each extremity and lead II ECG was also monitored continuously and data were stored on the hard disk. ECG calibration was performed using a square wave signal of 1-mV amplitude. After completion of the surgical procedures the animals were allowed to equilibrate for 15-30 min or until a stable MAP tracing was obtained (control period).

Premature ventricular complexes occurring during the 30 min immediately following intracerebroventricular (icv) L-glutamate injection were recorded. ST-segment shifts of more than 0.1 mV were also recorded and used as semiquantitative indicators of myocardial ischemia.

**Intracerebral injections**

The head of the animal was fixed in a stereotaxic frame (Unimécanique, Epinay/Seine, France) provided with modified ear bars and an attachment for infraorbital fixation. A craniotomy was performed and the dura mater cut to permit stereotaxic drug injections into the left lateral ventricle. L-glutamate (10 μmol) was injected in a constant volume of 100 μl of saline solution using a Hamilton microliter syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) at the following stereotaxic coordinates: AP, -4.5 mm from the bregma and L, -7.5 and -6.0 mm below the cranial surface (16). At the end of each experiment, the same volume (100 μl) Evans blue dye was injected under the same conditions. The brain was removed post mortem and dissected to determine whether the drugs had diffused properly throughout the ventricular space. Clonidine and rilmenidine were injected intracisternally (ic) in a constant volume of 50 μl directly into the cisterna magna.

**Experimental protocol**

L-glutamate (10 μmol, icv) was always injected 1 h after iv administration of the nitric oxide synthase inhibitor L-NAME (40 mg/kg) and the above mentioned cardiovascular parameters were continuously recorded (including the ECG).

In the control group, ventricular arrhythmia and ECG changes indicating myocardial ischemia were recorded for 30 min after L-glutamate injection (Figure 1A). In separate pretreated groups of animals, clonidine (1 μg/kg, ic or 10 μg/kg, iv), rilmenidine (30 μg/kg, ic or 300 μg/kg, iv) or propranolol (500 μg/kg, iv) was administered 10 min before the injection of L-NAME, and cardiac arrhythmia and ECG changes were monitored as above (Figure 1B). In the post-treated groups, clonidine (1 μg/kg, ic) or

![Figure 1. Schematic representation of the experimental protocols. L-NAME, N^o^-nitro-L-arginine methyl ester; iv, intravenous; ic, intracisternal.](image-url)
rilmenidine (3 or 30 µg/kg, \textit{ic}) were injected 10 min before L-glutamate and cardiac arrhythmia and ECG changes were monitored for 30 min (Figure 1C). A separate group of rabbits received only L-glutamate in order to investigate the effects of sympathetic hyperactivity in the absence of nitric oxide synthase inhibition (Figure 1D).

**Drugs**

Sodium pentobarbital, pancuronium bromide, L-NAME, L-glutamate, propranolol HCI and clonidine HCI were purchased from Sigma (St. Louis, MO, USA). Rilmenidine or (2-(N-(dicyclopropylmethylamino) oxazoline) was from Tockris Cookson Inc. (Ballwin, MO, USA). Drugs were dissolved in saline (0.9% NaCl).

**Statistical analysis**

All results are reported as means ± SEM for N experiments. The hemodynamic responses to L-glutamate injections were analyzed by the paired Student \( t \)-test. Comparisons between the hemodynamic parameters before and after drug injection within the same experimental groups were made by repeated measures ANOVA followed by the Tukey-Kramer test to determine significant differences. The data of ventricular premature beats (VPBmin), which did not have a Gaussian distribution, were transformed to natural log values and then analyzed by one-way ANOVA. When an overall difference was detected by ANOVA, the Student-Newman-Keuls test was used to determine significant differences. Fisher’s exact test was used to compare ST-segment shift and mortality rate data. P values of less than 0.05 were considered to be statistically significant. All calculations were made by computer-assisted analysis using a commercially available statistical package (Graphpad Instat, Graphpad Software, San Diego, CA, USA).

**Results**

**Basal cardiovascular parameters**

There were no significant differences in

---

Table 1. Hemodynamic effects of intravenous (\textit{iv}) administration of clonidine (CLO), rilmenidine (RIL) or propranolol (PRO) before injection of N6-nitro-L-arginine methyl ester (L-NAME, 40 mg/kg, \textit{iv}) and L-glutamate (GLU, 10 µmol, \textit{icv}) in pentobarbital-anesthetized rabbits.

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Drugs</th>
<th>MAP (mmHg)</th>
<th>HR (bpm)</th>
<th>dP/dtmax (mmHg/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonidine, 10 µg/kg, \textit{iv}, N = 8</td>
<td>Basal</td>
<td>100 ± 3</td>
<td>277 ± 14</td>
<td>2350 ± 80</td>
</tr>
<tr>
<td></td>
<td>CLO</td>
<td>81 ± 5*</td>
<td>252 ± 15</td>
<td>1788 ± 104*</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>100 ± 5*</td>
<td>242 ± 17</td>
<td>2213 ± 146*</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>132 ± 6*</td>
<td>210 ± 11*</td>
<td>2500 ± 141</td>
</tr>
<tr>
<td>Rilmenidine, 300 µg/kg, \textit{iv}, N = 10</td>
<td>Basal</td>
<td>109 ± 3</td>
<td>270 ± 5</td>
<td>2520 ± 105</td>
</tr>
<tr>
<td></td>
<td>RIL</td>
<td>80 ± 4*</td>
<td>224 ± 7*</td>
<td>1670 ± 88*</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>100 ± 3*</td>
<td>200 ± 7*</td>
<td>1990 ± 87*</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>136 ± 3*</td>
<td>182 ± 9</td>
<td>2300 ± 122*</td>
</tr>
<tr>
<td>Propranolol, 500 µg/kg, \textit{iv}, N = 7</td>
<td>Basal</td>
<td>107 ± 6</td>
<td>307 ± 8</td>
<td>2762 ± 148</td>
</tr>
<tr>
<td></td>
<td>PRO</td>
<td>104 ± 9</td>
<td>230 ± 4*</td>
<td>1864 ± 70*</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>114 ± 8</td>
<td>261 ± 6*</td>
<td>1873 ± 111</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>144 ± 7*</td>
<td>245 ± 10</td>
<td>2125 ± 144</td>
</tr>
</tbody>
</table>

All drugs were injected 10 min before L-NAME; L-glutamate was injected 60 min after L-NAME. MAP, mean arterial pressure; HR, heart rate; dP/dtmax, maximum rate of rise of left ventricular pressure. Data are reported as means ± SEM. N = number of experiments. 
*P<0.05 vs pre-injection values (Student-Newman-Keuls test).
mean basal values of MAP between the different experimental groups as shown by ANOVA (F = 1.933, P>0.05, N = 89); basal HR values were slightly but significantly higher in the experimental group treated iv with propranolol (F = 3.246, P<0.05; Tables 1, 2 and 3).

**Hemodynamic effects of iv injection of L-NAME**

When injected iv in non-pretreated rabbits, L-NAME (40 mg/kg) induced mild increases in MAP, which were statistically significant in only one experimental group

---

**Table 2. Hemodynamic effects of intracisternal (ic) administration of clonidine (CLO) and rilmenidine (RIL) before injection of N^o-nitro-L-arginine methyl ester (L-NAME, 40 mg/kg, iv) and L-glutamate (GLU, 10 µmol, icv) in pentobarbital-anesthetized rabbits.**

<table>
<thead>
<tr>
<th>Pretreatment</th>
<th>Drugs</th>
<th>MAP (mmHg)</th>
<th>HR (bpm)</th>
<th>dP/dt max (mmHg/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonidine, 1 µg/kg, ic; N = 8</td>
<td>Basal</td>
<td>109±3*</td>
<td>248±8</td>
<td>2669±85</td>
</tr>
<tr>
<td></td>
<td>CLO</td>
<td>82±4*</td>
<td>229±10</td>
<td>2115±123*</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>88±9</td>
<td>184±13*</td>
<td>1938±174</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>131±10*</td>
<td>184±2</td>
<td>2582±172*</td>
</tr>
<tr>
<td>Rilmenidine, 30 µg/kg, ic; N = 7</td>
<td>Basal</td>
<td>102±4</td>
<td>260±13</td>
<td>2455±95</td>
</tr>
<tr>
<td></td>
<td>CLO</td>
<td>75±6*</td>
<td>238±14</td>
<td>1660±213*</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>125±8*</td>
<td>194±20</td>
<td>2348±169*</td>
</tr>
</tbody>
</table>

CLO and RIL were injected 10 min before L-NAME; L-glutamate was injected 60 min after L-NAME. MAP, mean arterial pressure; HR, heart rate; dP/dt max, maximum rate of rise of left ventricular pressure. Data are reported as means ± SEM. N = number of experiments. *P<0.05 vs pre-injection values (Student-Newman-Keuls test).

---

**Table 3. Hemodynamic effects of intracisternal (ic) administration of clonidine (CLO) and rilmenidine (RIL) after N^o-nitro-L-arginine methyl ester (L-NAME, 40 mg/kg, iv) and before L-glutamate (GLU, 10 µmol, icv) in pentobarbital-anesthetized rabbits.**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Drugs</th>
<th>MAP (mmHg)</th>
<th>HR (bpm)</th>
<th>dP/dt max (mmHg/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clonidine, 1 µg/kg, ic; N = 8</td>
<td>Basal</td>
<td>93±3</td>
<td>247±11</td>
<td>1950±102</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>116±4*</td>
<td>233±16</td>
<td>1875±150</td>
</tr>
<tr>
<td></td>
<td>CLO</td>
<td>85±6*</td>
<td>211±18</td>
<td>1412±212*</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>129±5*</td>
<td>182±23*</td>
<td>1900±150</td>
</tr>
<tr>
<td>Rilmenidine, 3 µg/kg, ic; N = 8</td>
<td>Basal</td>
<td>92±5</td>
<td>244±8</td>
<td>2242±120</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>100±6</td>
<td>220±10</td>
<td>2396±232</td>
</tr>
<tr>
<td></td>
<td>RIL</td>
<td>97±7</td>
<td>214±16</td>
<td>2324±265</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>122±6*</td>
<td>202±12</td>
<td>2775±167</td>
</tr>
<tr>
<td>Rilmenidine, 30 µg/kg, ic; N = 7</td>
<td>Basal</td>
<td>107±10</td>
<td>258±9</td>
<td>2495±140</td>
</tr>
<tr>
<td></td>
<td>L-NAME</td>
<td>119±4</td>
<td>235±11</td>
<td>2699±91</td>
</tr>
<tr>
<td></td>
<td>RIL</td>
<td>84±8*</td>
<td>195±12*</td>
<td>1933±185*</td>
</tr>
<tr>
<td></td>
<td>GLU</td>
<td>126±10*</td>
<td>184±7</td>
<td>2458±176*</td>
</tr>
</tbody>
</table>

CLO and RIL were injected 10 min after L-NAME; L-glutamate was injected 5 min after CLO and RIL. MAP, mean arterial pressure; HR, heart rate; dP/dt max, maximum rate of rise of left ventricular pressure. Data are reported as means ± SEM. N = number of experiments. *P<0.05 vs pre-injection values (Student-Newman-Keuls test).
(clonidine 1 µg/kg, \textit{ic}; Table 3). HR and dP/dt\textsubscript{max} were not modified by L-NAME. In the pretreated groups of animals, L-NAME increased MAP in only two of six groups (clonidine 10 µg/kg, \textit{iv} and rilmenidine 300 µg/kg, \textit{iv}; Tables 1 and 2). HR fell significantly in two groups (rilmenidine 300 µg/kg, \textit{iv} and clonidine 1 µg/kg, \textit{ic}; Tables 1 and 2, respectively) and increased in the propranolol-pretreated group (Table 1). L-NAME also induced mild but significant increases in dP/dt\textsubscript{max} in groups pretreated with clonidine (10 µg/kg, \textit{iv}) and rilmenidine (300 µg/kg \textit{iv}; Table 1).

**Cardiovascular effects of the icv injection of L-glutamate in L-NAME-treated rabbits**

L-glutamate (10 µmol, \textit{icv}) triggered severe ventricular arrhythmia immediately after \textit{icv} injection (Figure 2): total number of VPB\textsubscript{min} was 30 ± 9 (N = 18) during the observation period (30 min). The incidence of ST-segment shift was 61% (11/18) and the mortality rate was 40% (7/18) (Figure 3). L-glutamate also induced significant increases in dP/dt\textsubscript{max} that reached a maximum of 23 ± 9% (1898 ± 241 before and 2245 ± 229 mmHg/s after L-glutamate administration; N = 18, P<0.05). The maximum increase in MAP was 31 ± 7% (112 ± 7 before and 143 ± 4 mmHg after L-glutamate administration; N = 18, P<0.05).

**Effects of L-glutamate in the absence of the nitric oxide synthase inhibitor**

The hemodynamic responses to L-glutamate alone were not significantly different from those of the L-NAME-treated groups (data not shown). The total number of VPB\textsubscript{min} in the 30-min period after L-glutamate injection was only 2 ± 2; we did not observe any ST-segment shift on the ECG, and all animals survived until the end of the experiment.

**Effects of treatments with clonidine, rilmenidine and propranolol on cardiovascular parameters**

The \textit{iv} administration of clonidine (10 µg/kg) and rilmenidine (300 µg/kg) before L-NAME (pretreated groups) induced significant hypotensive and negative inotropic effects; only rilmenidine elicited significant bradycardia at the doses used in this study (Table 1). On the other hand, systemic administration of propranolol (500 µg/kg, \textit{iv}) elicited significant bradycardia and reduction of dP/dt\textsubscript{max} which were not accompanied by arterial hypotension (Table 1). The \textit{ic} administration of a ten times lower dose of clonidine (1 µg/kg) and rilmenidine (30 µg/kg) under the same experimental conditions as above also induced significant arterial hypotension and reduction of dP/dt\textsubscript{max} (Table 1).

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{figure2.png}
\caption{Representative examples of the changes in ECG lead II tracings induced by the central injection of L-glutamate (10 µmol, \textit{icv}) in one \textit{N\textendash}nitro-L-arginine methyl ester (L-NAME, 40 mg/kg, \textit{iv})-treated pentobarbital-anesthetized rabbit. \textit{A}, Initial ECG. \textit{B}, ST-segment shift. \textit{C}, Premature ventricular complexes, after injection of L-NAME (40 mg/kg, \textit{iv}) followed by L-glutamate (10 µmol, \textit{icv}). These typical ECG recordings are representative of those obtained for 18 rabbits (control group).}
\end{figure}
2). When the same doses of clonidine and rilmenidine were injected 60 min after L-NAME (post-treated groups) hypotensive and negative inotropic responses were also observed; only rilmenidine induced a significant reduction in HR (Table 3). In contrast, a dose of rilmenidine (3 µg/kg) one hundred times lower than that injected systemically did not induce any significant cardiovascular effect after ic administration (Table 3). The hypertensive response to icv L-glutamate was not modified by the above-mentioned treatments but the increases in dP/dt_{max} were abolished by propranolol and were inconsistently attenuated by systemic or central administration of clonidine and rilmenidine (see Tables 1, 2 and 3).

Effects of intravenous treatments on the frequency of VPB_{min}, ST-segment shift and mortality rate

The iv treatment with clonidine (10 µg/kg), rilmenidine (300 µg/kg) and propranolol (500 µg/kg) significantly reduced the total number of VPB_{min} from 30 ± 9 to 18 ± 12, 9 ± 6 and 0, respectively (Figure 3). The incidence of ST-segment shift was also significantly reduced by these treatments. The mortality rate was only 12.5% (1/8, P = 0.3) in the group of animals pretreated with clonidine and all the animals pretreated with rilmenidine (P < 0.05) and propranolol (P = 0.1) survived up to 30 min after L-glutamate injection.

Effects of intracisternal treatments on the incidence of VPB_{min}, ST-segment shift and mortality rate

The ic administration of rilmenidine (30 µg/kg) but not of clonidine (1 µg/kg) 10 min before L-NAME significantly reduced the total number of VPB_{min} from 30 ± 9 to 9 ± 7 (Figure 4). Both drugs reduced the incidence of ST-segment shift and the mortality rate was reduced to zero in both groups. When
clonidine (1 µg/kg) or rilmenidine (3 or 30 µg/kg) was injected ic 1 h after L-NAME administration. The total number of VPB$_{min}$ was significantly reduced from 30 ± 9 to 7 ± 3, 2 ± 2 and 6 ± 3, respectively (Figure 5).

The mortality rate was markedly reduced by these treatments to 12.5% (1/8) in the group of animals pretreated with rilmenidine (3 µg/kg) and all animals pretreated with rilmenidine (30 µg/kg) and clonidine (1 µg/kg) survived up to 30 min after L-glutamate injection. As was the case for the pretreated groups of animals, the incidence of ST-segment shift was also reduced.

Analysis of overall mortality in all treated groups, regardless of whether they had been treated by the systemic or central route, showed a marked increase of survival rate in comparison to untreated animals (Figure 6).

**Discussion**

The main finding of the present study was that clonidine and rilmenidine, two centrally acting antihypertensive drugs (see Introduction), reduce the incidence of ventricular tachyarrhythmia and death in anesthetized rabbits experiencing myocardial ischemia during increased central sympathetic activity. It is noteworthy that the cardioprotective effects of rilmenidine can also be obtained with very low doses of the drug, with no significant hypotensive effect. The term cardioprotection is used throughout this paper in order to depict the beneficial effects of pharmacological approaches in the primary and/or secondary prevention of myocardial ischemia, cardiac electrical instability and sudden death. In fact, an updated definition of cardioprotection should include the beneficial effects of any pharmacological agent used to preserve the heart by preventing myocardial damage (17).

The clinical use of clonidine for the protection of the ischemic heart during surgery has been well established (18,19). Several clinical trials have shown that clonidine induces hemodynamic stability and reduces plasma catecholamine levels and myocardial oxygen demand in patients undergoing coronary artery bypass grafting, resulting in a decreased incidence of perioperative myo-
Cardioprotective effects of clonidine and rilmenidine

In fact, loss of autonomic balance characterized by increased sympathetic activity and decreased vagal activity is among the major cardiovascular risk factors (6). We have shown previously that the pharmacological stimulation of the central nervous system with L-glutamate injected into the lateral ventricle of rabbits markedly increases the sympathetic outflow to the periphery, resulting in important increases in myocardial oxygen consumption (8,25). It is noteworthy that successive stimulations are not possible in this experimental model since repeated injections of L-glutamate in the same animal lead to tachyphylaxis. Myocardial ischemia was induced by central nervous system activation with L-glutamate in L-NAME-treated rabbits. L-NAME is an analogue of L-arginine, which is known to competitively inhibit the enzyme nitric oxide synthase (26). It has been shown that acute blockade of the L-arginine-nitric oxide pathway induces systemic (27) as well as coronary vasoconstriction (28,29). Under our experimental conditions, the systemic treatment of anesthetized rabbits with a dose of 40 mg/kg L-NAME did not induce marked increases in arterial pressure or ischemic alterations of the ECG. Moreover, in spite of the important increases in cardiovascular parameters and myocardial oxygen consumption, L-glutamate alone did not evoke myocardial ischemia, demonstrating that the ECG changes observed in the L-NAME/L-glutamate-treated animals did not result from L-glutamate-induced increases in left ventricular afterload. On the other hand, ventricular arrhythmia, myocardial ischemia and death were observed immediately after activation of the central nervous system with L-glutamate in animals pretreated with L-NAME, proving sympathetic overactivity associated with a reduction of coronary blood flow to be highly deleterious to the heart. In the experimental protocol used in the present study, which did not include histopathological evaluation of the heart, the distinction between a transi-
tory ischemic effect and overt myocardial infarction was not possible. Nevertheless, the results of our study showed that the incidence of ventricular arrhythmia and myocardial ischemia as well as the mortality rate were markedly reduced or even completely abolished in animals systemically treated with hypotensive doses of clonidine (10 μg/kg) or rilmenidine (300 μg/kg). A similar cardioprotective effect was obtained with the i.v. injection of ten times lower doses of clonidine or rilmenidine, suggesting that this effect can be explained by a modulatory action on the central control of the sympathetic drive. In fact, clonidine and rilmenidine are known to inhibit the activity of sympathoexcitatory neurons in the ventrolateral medulla acting on α2-adrenoceptors and imidazoline receptors (11,12,30), resulting in a reduction of the activity of sympathetic preganglionic neurons. Treatment with i.v. clonidine (1 μg/kg) but not rilmenidine (3 or 30 μg/kg) was more effective when performed immediately before L-glutamate, probably because rilmenidine induces a longer-lasting effect after central administration. Interestingly, the central administration of low doses of rilmenidine (3 μg/kg), which did not induce arterial hypotension or cardiac depression, also elicited a cardioprotective effect in our experimental model. Thus, these results indicate a dissociation of the antiarrhythmic and antihypertensive properties of sympathomodulatory agents such as rilmenidine.

It has been well established from several large clinical trials that a β-blocker treatment of patients after myocardial infarction reduces the incidence of ventricular arrhythmia and the mortality rate (7). This cardioprotective action of β-blockers has mainly been attributed to a bradycardic effect associated with a beneficial influence of the drug on the autonomic control of heart rate, namely an inhibition on cardiac sympathetic drive (31). Furthermore, the main site of the central cardiovascular actions of clonidine and rilmenidine, namely the reticulospinal vasomotor neurons of the rostral ventrolateral medulla (9), which contribute significantly to the maintenance of tonic sympathetic vasomotor activity, is also involved in the central hypotensive effects of propranolol (32). Thus, it is reasonable to conclude that the cardioprotective effects of propranolol, at least under our experimental conditions, are partly due to its effects on the central nervous system. Finally, it is noteworthy that the blockade of β-adrenergic receptors induces important reductions of cardiac contractility, at least in experimental models of myocardial ischemia (3). This was not the case for the treatment with subhypotensive doses of rilmenidine (present study), which did not present any cardiodepressive effect while still eliciting a cardioprotective effect.

References

tors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection. Drugs, 58: 799-812.


